Navigation Links
Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Date:9/13/2012

NANJING, China, Sept. 13, 2012 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Mr. Hongquan Liu, as its Chief Executive Officer and Executive Director of the Board, effective October  8, 2012. Mr. Jinsheng Ren will continue to serve as Chairman of Simcere.

The Company also announced that Dr. Yehong Zhang, who currently serves as President of Simcere, will serve as Chief Executive Officer of Simcere MSD (Shanghai) Pharmaceutical Co. Ltd, the newly established joint venture between Simcere and Merck & Co., Inc. (NYSE: MRK), effective from October 8, 2012. Dr. Zhang will no longer hold the position of President of Simcere.  

Between 2000 and 2012, Mr. Hongquan Liu held the positions of Director and General Manager of Sino-Swed Pharmaceutical Corp. Ltd, the first pharmaceutical joint venture between China and Sweden. Prior to this, Mr. Liu held the positions of Chief Financial Officer and Chief Marketing and Business Officer of Pharmacia & Upjohn (China) Ltd., and General Manager of Pharmacia Corporation. Mr. Liu received an EMBA degree from China Europe International Business School (CEIBS) and a bachelor's degree from Shanxi College of Finance and Economics.

"I am delighted to welcome Hongquan to Simcere's management team," said Mr. Jinsheng Ren, Chairman of Simcere. "With nearly 30 years of management experience in the pharmaceutical industry, and as an Independent Director of Simcere for the last nine years, I am confident that as CEO, Hongquan will be instrumental in helping position Simcere for long-term sustainable growth.  With Hongquan leading the company's overall management and operations, I look forward to devoting more of my time to focusing on Simcere's mid- to long-term strategic direction and to building relationships with major stakeholders."

"I am very excited to join Simcere as Chief Executive Officer," said Mr. Liu. "With its abundant range of competitive products and solid management foundation, I am confident that Simcere has a promising future with high growth potential in China's rapidly developing pharmaceutical industry. I look forward to working alongside Mr. Ren and the entire management team to raise the quality of the company's operations and to strengthen its market competitiveness."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

 


In the United States:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: +1-425-985-5530

 

In Beijing:

Yue Yu

Brunswick Group

Tel: +86-10-5960-8600

In the United States:

Cindy Zheng

Brunswick Group LLC

Tel: +1-212-333-3810

 

 

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5000 


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
2. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
3. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
4. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
5. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
9. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
10. Chester County Biopharmaceutical Firm to Expand, Create 151 New Jobs
11. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)... , March 28, 2017  Today, Allergy & ... a new white paper to underscore the significant ... in healthcare. Specifically, there is substantial confusion as to the ... has urged manufacturers to drop the term "latex free" or ... the challenge to ensure a product is completely devoid of ...
(Date:3/28/2017)... Kingdom and  BOSTON , March 28, 2017 ... Linguamatics today announced a partnership with premium ... agreement allows pharmaceutical companies to extract key insights ... text mining technology. The Linguamatics ... the top 20 global pharmaceutical companies. The Linguamatics-Dow ...
Breaking Medicine Technology:
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
Breaking Medicine News(10 mins):